INM-755, an investigational cannabinol cream for epidermolysis bullosa (EB), showed a positive safety profile and did not interfere with normal healing in a Phase 1 clinical trial conducted in healthy volunteers with open wounds, according to a press release from the cream’s developer, InMed Pharmaceuticals. INM-755 is a topical cream that contains cannabinol (CBN), a molecule found in small amounts in the cannabis plant. The cream is being developed to treat symptoms of EB and other skin…

You must be logged in to read/download the full post.